THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL No. 454 Session of 2001

INTRODUCED BY O'BRIEN, DAILEY, BELARDI, BENNINGHOFF, CALTAGIRONE, CAPPABIANCA, CAWLEY, CLARK, CLYMER, CORRIGAN, CRUZ, DeLUCA, DeWEESE, FAIRCHILD, FLEAGLE, FRANKEL, GEORGE, GRUCELA, HARHAI, HASAY, HENNESSEY, HERMAN, HORSEY, KENNEY, LAUGHLIN, LEDERER, MANN, McCALL, McNAUGHTON, MELIO, MICOZZIE, MUNDY, ORIE, PIPPY, PRESTON, RUBLEY, SATHER, SAYLOR, SHANER, SOLOBAY, STABACK, STEELMAN, T. STEVENSON, E. Z. TAYLOR, THOMAS, TIGUE, WALKO, C. WILLIAMS, WILT, WOJNAROSKI, YEWCIC AND YOUNGBLOOD, FEBRUARY 5, 2001

REFERRED TO COMMITTEE ON HEALTH AND HUMAN SERVICES, FEBRUARY 5, 2001

AN ACT

Requiring the Department of Health to establish bloodborne
 pathogen standards for public employees; and establishing the
 Bloodborne Pathogen Fund.

4 The General Assembly of the Commonwealth of Pennsylvania

5 hereby enacts as follows:

6 Section 1. Short title.

7 This act shall be known and may be cited as the Bloodborne

8 Pathogen Standard Act.

9 Section 2. Definitions.

10 The following words and phrases when used in this act shall

11 have the meanings given to them in this section unless the

12 context clearly indicates otherwise:

13 "Bloodborne pathogen." A pathogenic microorganism which is14 present in human blood and can cause disease in humans. The term

includes hepatitis B virus (HBV), hepatitis C virus (HCV) and
 human immunodeficiency virus (HIV).

3 "Department." The Department of Health of the Commonwealth.
4 "Employer." An employer having public employees with
5 occupational exposure to blood or other material potentially
6 containing a bloodborne pathogen.

7

"Engineered sharps injury protection." Any of the following:

8 (1) A physical attribute built into a needle device used 9 for withdrawing body fluids, accessing a vein or artery or 10 administering medications or other fluids, which effectively 11 reduces the risk of an exposure incident by a mechanism such 12 as barrier creation, blunting, encapsulation, withdrawal, 13 retraction, destruction or other effective mechanisms.

14 (2) A physical attribute built into any other type of
15 needle device or into a nonneedle sharp which effectively
16 reduces the risk of an exposure incident.

17 "Front-line health care worker." A nonmanagerial employee 18 responsible for direct patient care with potential occupational 19 exposure to a sharps injury.

20 "Fund." The Bloodborne Pathogen Fund established in section21 4.

22 "Needleless system." A device which does not utilize needles23 for:

(1) the withdrawal of body fluids after initial venousor arterial access is established;

(2) the administration of medication or fluids; or
(3) any other procedure involving the potential for an
exposure incident.

29 "Public employee." An employee of the Commonwealth or a 30 political subdivision employed in a health care facility, home 20010H0454B0489 - 2 - health care organization or other facility providing health
 care-related services.

3 "Sharp." An object used or encountered in a health care
4 setting which can be reasonably anticipated to penetrate the
5 skin or any other part of the body and to result in an exposure
6 incident. The term includes a needle device, scalpel or lancet;
7 broken glass; or a broken capillary tube.

8 "Sharps injury." An injury caused by a sharp. The term9 includes any cut, abrasion or needlestick.

10 "Sharps injury log." A written or electronic record of 11 sharps injuries.

12 Section 3. Department.

(a) Adoption of standard.--Within six months of the effective date of this act, the department shall promulgate regulations adopting a bloodborne pathogen standard governing public employees. The standard shall be at least as prescriptive as the standard promulgated by the Federal Occupational Safety and Health Review Commission and shall include the following:

19 (1) A requirement that needleless systems and sharps
20 with engineered sharps injury protection be included as
21 engineering and work practice controls. Engineering controls
22 under this paragraph shall not be required if:

(i) none is available in the marketplace; or
(ii) an evaluation committee, as described in
paragraph (2)(iii)(C)(X), determines by means of
objective product evaluation criteria that use of such
devices will jeopardize patient or employee safety with
regard to a specific medical procedure.

29 (2) A requirement that each employer develop and 30 implement an effective written exposure control plan which 20010H0454B0489 - 3 - 1

includes procedures for all of the following:

2 (i) Identifying and selecting needleless systems and
3 sharps with engineered sharps injury protection through
4 the evaluation committee described in subparagraph
5 (iii)(C)(X).

6 (ii) Updating the written exposure control plan when 7 necessary, but at least once each year, to reflect 8 progress in implementing needleless systems and sharps 9 with engineered sharps injury protection as determined by 10 the evaluation committee under subparagraph (iii)(C)(X).

(iii) Recording information concerning exposure
 incidents in a sharps injury log. This subparagraph
 includes:

14

(A) Date and time of the exposure incident.

15 (B) Type and brand of sharp involved in the16 exposure incident.

17 (C) Description of the exposure incident. This18 clause includes:

19 (I) Job classification of the exposed public20 employee.

(II) Department or work area where theexposure incident occurred.

(III) Procedure which the exposed public
employee was performing at the time of the
incident.

26 (IV) How the incident occurred.

27 (V) Body part involved in the exposure28 incident.

29(VI) If the sharp had engineered sharps30injury protection, whether the protective

20010H0454B0489

- 4 -

mechanism was activated and whether the injury occurred before the protective mechanism was activated, during activation of the mechanism or after activation of the mechanism.

(VII) If the sharp had no engineered sharps injury protection, whether and how such a mechanism could have prevented the injury. This subclause requires statement of the basis for the assessment.

10 (VIII) An assessment of whether any other 11 engineering, administrative or work practice 12 control could have prevented the injury. This 13 subclause requires statement of the basis for the 14 assessment.

15 (IX) Ensuring that all front-line health
16 care workers are trained on the use of all
17 engineering controls before they are introduced
18 into the clinical setting.

19 (X) Establishing an evaluation committee, at 20 least half the members of which are public front-21 line health care workers from a variety of 22 occupational classifications and departments, 23 including nurses, nurse aides, technicians, 2.4 phlebotomists and physicians, to advise the 25 employer on the implementation of the 26 requirements of the regulations. Members of the 27 committee shall be trained in the proper method 28 of utilizing product evaluation criteria prior to 29 the commencement of product evaluation. 30 (b) Additional measures. -- The department shall consider

20010H0454B0489

1

2

3

4

5

6

7

8

9

- 5 -

additional measures to prevent sharps injuries or exposure
 incidents. This subsection includes training and educational
 requirements, increased use of vaccinations, strategic placement
 of sharps containers as close to the work area as practical and
 increased use of personal protective equipment.

(c) Transitional period for certain drugs and biologics.--6 7 The use of a drug or biologic which is prepackaged with an administration system or used in a prefilled syringe and is 8 approved for commercial distribution or investigational use by 9 10 the Federal Food and Drug Administration is exempt for a 11 standard adopted under subsection (a) or additional measures adopted under subsection (b) for a period of three years from 12 13 the effective date of this act.

14 Compilation and maintenance of list. -- The department (d) 15 shall compile and maintain a list of needleless systems and 16 sharps with engineered sharps injury protection. The list shall 17 be available to assist employers in complying with the 18 requirements of the regulations promulgated under this section. 19 The list may be developed from existing sources of information, 20 including the Federal Food and Drug Administration, the Federal Centers for Disease Control, the National Institute of 21 22 Occupational Safety and Health and the United States Department 23 of Veterans Affairs.

24 Section 4. Fund.--

(a) Establishment.--The Bloodborne Pathogen Fund isestablished in the State Treasury.

(b) Purposes.--The department shall utilize the fund to doall of the following:

29 (1) Implement this act.

30 (2) In needleless systems and sharps with engineered 20010H0454B0489 - 6 - sharps injury protection, provide for research, development
 and product evaluation.

3 (c) Source.--The source of the fund is appropriations.

4 (d) Continuous appropriation.--The money in the fund is
5 continuously appropriated to the fund. This appropriation shall
6 not lapse at the end of any fiscal year.

7 Section 5. Effective date.

8 This act shall take effect in 120 days.